Previously Hidden FDA Data Reveal a Multitude of Adverse Events Linked to Breast Implants
Why were adverse events reported through an alternative reporting channel as opposed to a more transparent means?
All articles by Agata Boxe
New Trial Attempts to Make Genetic Counseling and Testing More Accessible
The researchers wrote that “genetic counseling must be further explored to find an optimal balance of clinical quality with increased access and financial sustainability.”
Research Examines Breast Cancer Susceptibility Genes in Hispanic Women and Other Diverse Populations
The presence of CHEK2 or PALB2 variants in Hispanic women is enough to warrant the addition of an annual breast MRI, said study authors.
Analysis Sheds Light on Bevacizumab “Reversals” in Glioblastoma
Improvements to PFS and “clinically meaningful reductions in daily corticosteroid use” were said to be linked to the addition of bevacizumab in glioblastoma.
How to Treat Melanoma After Checkpoint Inhibitors Fail
The combination of ipilimumab and nivolumab resulted in a higher rate of objective remissions compared with ipilimumab alone.
Adjuvant Ipilimumab Determined to Increase Overall Survival in High-Risk Melanoma
Adjuvant ipilimumab may improve overall survival in patients with resected high-risk melanoma.
Neoadjuvant Therapy in Melanoma Tied to High Pathological Response Rates
Researchers concluded that the ability to achieve pCR correlated to improved recurrence-free survival in melanoma.
No Link Found Between HRD and Pathologic Response in Triple-Negative Breast Cancer
One of the study’s primary objectives was to detect an association between homologous repair deficiency and pathologic response.
Paclitaxel Plus Olaparib Linked to Better Outcomes in Some Breast Cancer Patients
Paclitaxel plus olaparib may result in a higher pathological complete response (pCR) rate than paclitaxel plus carboplatin — followed by epirubicin and cyclophosphamide — but only in some groups of patients.
Extended Letrozole Provides Benefit After Adjuvant Tamoxifen
Extended adjuvant treatment with additional 5 years of letrozole was associated with a 19% reduction in invasive disease-free survival events, said authors.
Next post in ASCO 2019 Breast Cancer In Depth
